Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 132Magnetic Resonance Spectroscopy 107Biopsy 79pembrolizumab 66Nivolumab 63Carboplatin 62Cisplatin 60Cyclophosphamide 56Paclitaxel 47Radiotherapy 37Gemcitabine 37Bevacizumab 36Dexamethasone 33Pemetrexed 28Rituximab 27Fluorouracil 27Doxorubicin 26olaparib 25Injections 25fludarabine 24durvalumab 24atezolizumab 24Radiation 24Ipilimumab 23Docetaxel 23Oxaliplatin 22Cytarabine 22venetoclax 21Vincristine 21Taxes 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × itacitinib × 30 days × Clear all
NCT05364762 2026-06-03

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

City of Hope Medical Center

Phase 2 Active not recruiting
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡